CL2008000762A1 - Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02). - Google Patents

Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).

Info

Publication number
CL2008000762A1
CL2008000762A1 CL200800762A CL2008000762A CL2008000762A1 CL 2008000762 A1 CL2008000762 A1 CL 2008000762A1 CL 200800762 A CL200800762 A CL 200800762A CL 2008000762 A CL2008000762 A CL 2008000762A CL 2008000762 A1 CL2008000762 A1 CL 2008000762A1
Authority
CL
Chile
Prior art keywords
compounds
pyrimidins
psoriasis
diabetes
diseases
Prior art date
Application number
CL200800762A
Other languages
English (en)
Spanish (es)
Inventor
Ernest Wolcox Mark Edwar Glenn
Original Assignee
Pfizer Products Inc Sa Organiz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26968730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000762(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc Sa Organiz filed Critical Pfizer Products Inc Sa Organiz
Publication of CL2008000762A1 publication Critical patent/CL2008000762A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200800762A 2001-05-31 2008-03-14 Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02). CL2008000762A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29477501P 2001-05-31 2001-05-31
US34104801P 2001-12-06 2001-12-06

Publications (1)

Publication Number Publication Date
CL2008000762A1 true CL2008000762A1 (es) 2008-07-04

Family

ID=26968730

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200800762A CL2008000762A1 (es) 2001-05-31 2008-03-14 Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).

Country Status (52)

Country Link
US (2) US7301023B2 (2)
EP (3) EP1609781B1 (2)
JP (1) JP4381137B2 (2)
KR (5) KR100869409B1 (2)
CN (1) CN1729192A (2)
AP (1) AP1859A (2)
AR (2) AR037321A1 (2)
AT (1) ATE519741T1 (2)
AU (2) AU2002304401C1 (2)
BE (1) BE2017C032I2 (2)
BG (1) BG66489B1 (2)
BR (1) BR0209246A (2)
CA (1) CA2448281C (2)
CL (1) CL2008000762A1 (2)
CR (1) CR10177A (2)
CU (1) CU23337B7 (2)
CY (2) CY1113322T1 (2)
CZ (1) CZ304366B6 (2)
DK (1) DK1666481T3 (2)
EA (2) EA007251B1 (2)
EC (1) ECSP034865A (2)
EE (1) EE05332B1 (2)
ES (2) ES2369226T3 (2)
FR (1) FR17C1031I2 (2)
GE (1) GEP20063784B (2)
GT (2) GT200200100A (2)
HR (1) HRP20030943B1 (2)
HU (2) HU230876B1 (2)
IL (1) IL158588A0 (2)
IS (1) IS3023B (2)
LT (1) LTC1666481I2 (2)
LU (1) LUC00031I2 (2)
MA (1) MA27029A1 (2)
MX (1) MXPA03011062A (2)
MY (1) MY129649A (2)
NL (1) NL300887I2 (2)
NO (3) NO328578B1 (2)
NZ (2) NZ540332A (2)
OA (1) OA12612A (2)
PA (1) PA8546301A1 (2)
PE (1) PE20030561A1 (2)
PL (2) PL228155B1 (2)
PT (1) PT1666481E (2)
RS (1) RS52144B (2)
SI (1) SI1666481T1 (2)
SK (2) SK288199B6 (2)
TN (1) TNSN03128A1 (2)
TW (2) TWI310384B (2)
UA (1) UA80093C2 (2)
UY (1) UY27317A1 (2)
WO (1) WO2002096909A1 (2)
ZA (1) ZA200307982B (2)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339167B2 (en) 2017-12-28 2022-05-24 Daewoong Pharmaceutical Co., Ltd. Substituted piperidines as kinase inhibitors

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
HRP20021000A2 (en) * 2000-06-26 2005-02-28 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
PY0228255A (es) 2001-12-06 2004-06-01 Pfizer Prod Inc Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
CN1678314A (zh) * 2002-08-27 2005-10-05 默克专利有限公司 作为raf－激酶抑制剂的甘氨酸酰胺衍生物
CN1717236A (zh) 2002-11-26 2006-01-04 辉瑞产品公司 治疗移植排斥的方法
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
JP2007536310A (ja) * 2004-05-03 2007-12-13 ノバルティス アクチエンゲゼルシャフト Ｓ１ｐ受容体アゴニストおよびｊａｋ３キナーゼ阻害剤を含む、組合せ剤
CA2572314A1 (en) 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity
TW200615268A (en) 2004-08-02 2006-05-16 Osi Pharm Inc Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1885352A2 (en) * 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7491732B2 (en) 2005-06-08 2009-02-17 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CN102127078A (zh) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
EP1910358A2 (en) 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
PT1913000E (pt) 2005-07-29 2012-02-28 Pfizer Prod Inc Derivados de pirrolo[2,3-d]pirimidina, suas substâncias intermédias e processo de síntese
EP1926735A1 (en) 2005-09-22 2008-06-04 Incyte Corporation Tetracyclic inhibitors of janus kinases
PT2348023E (pt) 2005-12-13 2015-09-15 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
US8962643B2 (en) 2006-02-24 2015-02-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
ES2415863T3 (es) 2006-12-22 2013-07-29 Incyte Corporation Heterociclos sustituidos como inhibidores de Janus Quinasas
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
ES2714092T3 (es) 2007-06-13 2019-05-27 Incyte Holdings Corp Uso de sales del inhibidor de quinasas Janus (R)-3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
AU2008273804B2 (en) * 2007-07-11 2014-07-10 Pfizer Inc. Pharmaceutical compositions and methods of treating dry eye disorders
DK2265607T3 (en) 2008-02-15 2017-03-13 Rigel Pharmaceuticals Inc PYRIMIDIN-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
SI2288610T1 (sl) 2008-03-11 2016-11-30 Incyte Holdings Corporation Derivati azetidina in ciklobutana kot inhibitorji jak
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
KR20110050654A (ko) * 2008-08-01 2011-05-16 바이오크리스트 파마수티컬즈, 인코퍼레이티드 Ｊａｋ3 억제제로서의 피페리딘 유도체
CA2733359C (en) 2008-08-20 2014-08-05 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
EP2396004A4 (en) * 2009-02-11 2012-07-25 Reaction Biology Corp SELECTIVE KINASE HEMMER
JP5709276B2 (ja) 2009-04-20 2015-04-30 オースペックス ファーマシューティカルズ，エルエルシー ヤヌスキナーゼ３のピペリジンインヒビター
SG176130A1 (en) 2009-05-22 2011-12-29 Incyte Corp N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
ME03556B (me) 2009-05-22 2020-07-20 Incyte Holdings Corp 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1 h-pirazol-1-il]oktan- ili нертan - niтril kао јак inhibiтori
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
JP5658756B2 (ja) * 2009-09-10 2015-01-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊａｋの阻害剤
US8486902B2 (en) 2009-10-09 2013-07-16 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
PE20121077A1 (es) 2009-10-15 2012-08-10 Pfizer Compuestos de pirrolo[2,3-d]pirimidina
JP5739446B2 (ja) 2009-12-18 2015-06-24 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
BR112012017269A2 (pt) * 2010-01-12 2016-05-03 Hoffmann La Roche compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
CA2788071A1 (en) 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
TWI694826B (zh) 2010-03-10 2020-06-01 美商英塞特公司 作為ｊａｋ１抑制劑之哌啶-４-基三亞甲亞胺衍生物
MY178634A (en) 2010-05-21 2020-10-19 Incyte Corp Topical formulation for a jak inhibitor
TW201300360A (zh) 2010-11-01 2013-01-01 Portola Pharm Inc 做為ｊａｋ激酶調節劑之菸鹼醯胺
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CA2818545C (en) 2010-11-19 2019-04-16 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2481411A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
EP2481397A1 (en) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmaceutical compositions comprising tasocitinib
WO2012112847A1 (en) 2011-02-18 2012-08-23 Novartis Pharma Ag mTOR/JAK INHIBITOR COMBINATION THERAPY
WO2012135338A1 (en) 2011-03-28 2012-10-04 Ratiopharm Gmbh Processes for preparing tofacitinib salts
US9050342B2 (en) 2011-03-29 2015-06-09 Pfizer Inc. Beneficial effects of combination therapy on cholesterol
SG193245A1 (en) * 2011-04-08 2013-10-30 Pfizer Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
EP2741747A1 (en) 2011-08-10 2014-06-18 Novartis Pharma AG JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
US10821111B2 (en) 2011-11-30 2020-11-03 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3750544B1 (en) * 2011-11-30 2025-03-05 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013090490A1 (en) 2011-12-15 2013-06-20 Ratiopharm Gmbh Tofacitinib salts
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2014016338A1 (en) 2012-07-25 2014-01-30 Lek Pharmaceuticals D.D. New synthetic route for the preparation of 3-amino-piperidine compounds
EP2903970A4 (en) 2012-10-08 2016-11-30 Portola Pharm Inc SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
KR20210037012A (ko) 2012-11-15 2021-04-05 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
CN104955803B (zh) * 2012-11-30 2017-11-28 斯洛文尼亚莱柯制药股份有限公司 通过硝基‑四氢吡啶前体制备3‑氨基‑哌啶化合物
US9481679B2 (en) 2012-12-17 2016-11-01 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
US9670160B2 (en) 2012-12-28 2017-06-06 Glenmark Pharmaceuticals Limited Process for the preparation of tofacitinib and intermediates thereof
WO2014128591A1 (en) 2013-02-22 2014-08-28 Pfizer Inc. Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)
SI2964650T1 (sl) 2013-03-06 2019-05-31 Incyte Holdings Corporation Postopki in vmesne spojine za izdelavo inhibitorja JAK
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20140343034A1 (en) 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
CN104513248B (zh) * 2013-09-30 2019-05-24 重庆医药工业研究院有限责任公司 一种托法替尼中间体的纯化方法
ES2871524T3 (es) 2013-12-05 2021-10-29 Pfizer Pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinilo y pirrolo[2,3-d]piridinil acrilamidas
SI2994454T1 (sl) * 2013-12-09 2019-05-31 Unichem Laboratories Limited Izboljšan postopek za pripravo (3R,4R)-(1-benzil-4-metil piperidin-3-il)-metil amina
CA2881262A1 (en) 2014-02-06 2015-08-06 Prabhudas Bodhuri Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CA2979425C (en) * 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd Jak inhibitor
EP3162793B1 (en) * 2015-02-17 2019-04-10 Amorepacific Corporation Chiral resolution method of n-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives
CN104761556B (zh) * 2015-03-21 2017-06-23 河北国龙制药有限公司 托法替布中间体杂质、托法替布杂质及其合成方法，以及托法替布的质量监控方法
EP3078665A1 (en) 2015-04-10 2016-10-12 OLON S.p.A. Efficient method for the preparation of tofacitinib citrate
UA119701C2 (uk) 2015-04-29 2019-07-25 Вуксі Фортуне Фармасьютікал Ко., Лтд Піримідинові сполуки як jak-інгібітори
JP6761815B2 (ja) 2015-05-01 2020-09-30 ファイザー・インク ピロロ［２，３−ｄ］ピリミジニル、ピロロ［２，３−ｂ］ピラジニル、ピロロ［２，３−ｂ］ピリジニルアクリルアミド、およびそのエポキシド
PL3305788T3 (pl) 2015-05-29 2021-03-08 Wuxi Fortune Pharmaceutical Co., Ltd Inhibitor kinazy janusowej
JP6507272B2 (ja) * 2015-07-27 2019-04-24 ユニケム ラボラトリーズ リミテッド トファシチニブ口腔内崩壊錠
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
WO2017091681A1 (en) 2015-11-24 2017-06-01 Aclaris Therapeutics, Inc. Selective kinase inhibitors
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
KR102565407B1 (ko) * 2016-01-04 2023-08-10 (주)아모레퍼시픽 극성 비양자성 용매를 이용한 n-[4-(1-아미노에틸)-페닐]-술폰아미드 유도체의 카이랄 분할 방법
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
MX388591B (es) 2016-06-30 2025-03-20 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
CN107602569A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种新型吡咯并[2,3‑d]嘧啶化合物及其合成方法和用途
KR102078805B1 (ko) 2017-11-30 2020-02-19 보령제약 주식회사 토파시티닙을 포함하는 약제학적 조성물
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
KR102577241B1 (ko) 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체
KR102577242B1 (ko) * 2017-12-28 2023-09-11 주식회사 대웅제약 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체
UA127488C2 (uk) 2018-01-30 2023-09-06 Інсайт Корпорейшн Способи одержання (1-(3-фтор-2-(трифторметил)ізонікотиноїл)піперидин-4-ону)
CA3089108A1 (en) * 2018-01-31 2019-08-08 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
US12161748B2 (en) 2018-01-31 2024-12-10 Twi Biotechnology, Inc. Topical formulations comprising tofacitinib
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
KR102131107B1 (ko) 2019-01-15 2020-07-07 주식회사 다산제약 3-아미노-피페리딘 화합물의 신규한 제조 방법
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
US12364696B2 (en) 2019-02-27 2025-07-22 Jak Slave Pty Ltd Treatment of autoimmune disease
CA3132109A1 (en) 2019-03-13 2020-09-17 Intas Pharmaceuticals Ltd. Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
CN113993585B (zh) 2019-03-27 2024-10-01 英矽智能科技知识产权有限公司 双环jak抑制剂及其用途
KR102890724B1 (ko) * 2019-04-05 2025-11-25 주식회사유한양행 (3r,4r)-1-벤질-n,4-디메틸피페리딘-3-아민 또는 이의 염의 제조방법 및 이를 이용한 토파시티닙의 제조방법
EP4054527A4 (en) 2019-11-08 2023-12-06 Cage Bio Inc. TOPICAL ADMINISTRATION OF TOFACITINIB USING IONIC LIQUID
EP4057989A1 (en) 2019-11-14 2022-09-21 Pfizer Inc. 1-(((2s,3s,4s)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
JP7371253B2 (ja) 2019-11-25 2023-10-30 デウン ファーマシューティカル カンパニー リミテッド 新規なトリアゾロピリジン誘導体およびこれを含む薬学組成物
US20230149407A1 (en) 2020-04-04 2023-05-18 Pfizer Inc. Methods of Treating Coronavirus Disease 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022194782A1 (en) * 2021-03-15 2022-09-22 Chiesi Farmaceutici S.P.A. Heterocyclic derivatives as janus kinase inhibitors
CN113549075B (zh) * 2021-06-23 2025-09-23 合肥华方医药科技有限公司 一种枸橼酸托法替布非对映异构体杂质的合成方法
EP4180042A1 (en) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. A film coated tablet comprising micronized tofacitinib

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (es) 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
JPH07330732A (ja) * 1994-06-10 1995-12-19 Kyorin Pharmaceut Co Ltd 光学活性な３−アミノ−１−ベンジルピペリジン誘導体
US6136596A (en) * 1995-05-19 2000-10-24 University Of Massachusetts Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
DE69531558T2 (de) 1995-06-07 2004-03-18 Pfizer Inc. Heterocyclische kondensierte pyrimidin-derivate
BR9609613A (pt) 1995-07-05 1999-05-25 Du Pont Composto composição fungicida e método de controle de doenças de plantas
CN1100778C (zh) 1995-07-06 2003-02-05 诺瓦蒂斯有限公司 吡咯并嘧啶及其制备方法
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
BR9607089A (pt) 1995-11-14 1997-11-11 Pharmacia & Upjohn Spa Compostos de pirimidina condensada biciclica composição farmacéutica utilização e produtos que contém os mesmos e processo para a preparação desses compostos
EP0888349B1 (en) 1996-01-23 2002-05-22 Novartis AG Pyrrolopyrimidines and processes for their preparation
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
PL331154A1 (en) 1996-07-13 1999-06-21 Glaxo Group Ltd Bicyclic heteroaromatic compounds as inhibitors of proteinous tyrosine kinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2262421C (en) 1996-08-23 2007-10-02 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
US6413971B1 (en) 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
US6187552B1 (en) 1997-03-24 2001-02-13 Pharmacia & Upjohn Company Method for identifying inhibitors of JAK2/cytokine receptor binding
EP1068206A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted pyrrolo 2,3-b]pyridine and pyrrolo 2,3-d]pyrimidine derivatives: modulators of crf1 receptors
WO1999061428A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
EP1087970B1 (en) * 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2000000202A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
JP2002523403A (ja) 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
KR100477818B1 (ko) * 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
HRP20021000A2 (en) * 2000-06-26 2005-02-28 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS IMMUNOSUPPRESSIVE AGENTS
PY0228255A (es) * 2001-12-06 2004-06-01 Pfizer Prod Inc Compuestos cristalinos novedosos
CA2572314A1 (en) * 2004-06-29 2006-01-12 Christopher N. Farthing Pyrrolo[2,3-d]pyrimidines that modulate ack1 and lck activity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11339167B2 (en) 2017-12-28 2022-05-24 Daewoong Pharmaceutical Co., Ltd. Substituted piperidines as kinase inhibitors

Also Published As

Publication number Publication date
TW200413370A (en) 2004-08-01
SK288199B6 (sk) 2014-06-03
TNSN03128A1 (fr) 2005-12-23
LTPA2017025I1 (lt) 2017-09-11
CA2448281C (en) 2009-05-05
LUC00031I1 (2) 2017-08-10
NO20035201D0 (no) 2003-11-24
KR100868814B1 (ko) 2008-11-14
CU23337B7 (es) 2009-01-20
KR100926875B1 (ko) 2009-11-16
US20030073719A1 (en) 2003-04-17
AP2002002550A0 (en) 2002-06-30
AR045680A2 (es) 2005-11-09
NZ530380A (en) 2005-08-26
NO20093135L (no) 2003-11-24
OA12612A (en) 2006-06-09
EP1392694A1 (en) 2004-03-03
CY1113322T1 (el) 2016-06-22
GEP20063784B (en) 2006-04-10
AU2008203170B2 (en) 2009-06-18
IS3023B (is) 2020-08-15
JP4381137B2 (ja) 2009-12-09
BE2017C032I2 (2) 2021-07-19
UY27317A1 (es) 2003-02-28
EA200301193A1 (ru) 2004-04-29
US7301023B2 (en) 2007-11-27
WO2002096909A1 (en) 2002-12-05
ATE519741T1 (de) 2011-08-15
BG66489B1 (bg) 2015-05-29
CR10177A (es) 2008-08-19
CZ20033260A3 (en) 2004-03-17
IS6993A (is) 2003-10-13
EP1666481B1 (en) 2012-09-19
NZ540332A (en) 2007-05-31
EA012666B1 (ru) 2009-12-30
LTC1666481I2 (lt) 2018-06-25
ES2393385T3 (es) 2012-12-20
HUS1900008I1 (hu) 2020-02-28
US20040229923A1 (en) 2004-11-18
AU2002304401B2 (en) 2008-04-17
ZA200307982B (en) 2004-10-14
AU2002304401C1 (en) 2009-03-05
AU2008203170A1 (en) 2008-08-07
HRP20030943B1 (hr) 2011-11-30
CY2017028I1 (el) 2018-02-14
SK288192B6 (sk) 2014-06-03
EP1666481A2 (en) 2006-06-07
EE200300594A (et) 2004-04-15
YU92303A (sh) 2006-08-17
ECSP034865A (es) 2004-01-28
PL228155B1 (pl) 2018-02-28
JP2004534047A (ja) 2004-11-11
CZ304366B6 (cs) 2014-04-02
GT200200100AA (es) 2007-07-06
PL367945A1 (en) 2005-03-07
KR20080083028A (ko) 2008-09-12
ES2369226T3 (es) 2011-11-28
MY129649A (en) 2007-04-30
IL158588A0 (en) 2004-05-12
CY2017028I2 (el) 2018-02-14
HRP20030943A2 (en) 2005-08-31
EE05332B1 (et) 2010-08-16
GT200200100A (es) 2003-02-11
MA27029A1 (fr) 2004-12-20
EP1609781B1 (en) 2011-08-10
HUP0400152A3 (en) 2012-12-28
SK14652003A3 (sk) 2004-05-04
EP1666481A3 (en) 2006-11-29
KR20080002931A (ko) 2008-01-04
EP1609781A1 (en) 2005-12-28
TWI316061B (en) 2009-10-21
NO328578B1 (no) 2010-03-22
EA200600575A1 (ru) 2006-08-25
PL409305A1 (pl) 2014-12-22
HU230876B1 (hu) 2018-11-29
PT1666481E (pt) 2012-12-03
FR17C1031I2 (fr) 2018-11-02
SI1666481T1 (sl) 2012-11-30
KR20060014459A (ko) 2006-02-15
CA2448281A1 (en) 2002-12-05
BG108389A (bg) 2005-01-31
RS52144B (sr) 2012-08-31
CN1729192A (zh) 2006-02-01
AP1859A (en) 2008-07-02
NO2017047I1 (no) 2017-09-08
LUC00031I2 (2) 2017-10-11
KR20060133117A (ko) 2006-12-22
AR037321A1 (es) 2004-11-03
KR100869409B1 (ko) 2008-11-21
NO20035201L (no) 2003-11-24
PA8546301A1 (es) 2003-05-14
DK1666481T3 (da) 2012-10-15
US7432370B2 (en) 2008-10-07
NL300887I2 (nl) 2017-08-31
UA80093C2 (uk) 2007-08-27
HUP0400152A2 (en) 2007-07-30
EP1666481B9 (en) 2013-05-01
EA007251B1 (ru) 2006-08-25
FR17C1031I1 (fr) 2017-10-13
PE20030561A1 (es) 2003-06-23
MXPA03011062A (es) 2004-03-19
BR0209246A (pt) 2004-06-15
TWI310384B (en) 2009-06-01
KR20040003037A (ko) 2004-01-07

Similar Documents

Publication Publication Date Title
CL2008000762A1 (es) Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la psoriasis, diabetes, artritis reumatoide, entre otras enfermedades ( divisional solicitud 1147-02).
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
BRPI0208957B8 (pt) composto, uso de um composto, composição farmacêutica e sal
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
DOP2002000429A (es) Imidazotriazinas
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
DE60228761D1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
ES2178298T3 (es) Compuestos anti-inflamatorios.
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BR0309546A (pt) Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii
CL2003002731A1 (es) Compuesto derivado de quinazolina de formula definida, que actua como inhibidor de la kinasa aurora; procedimiento de preparacion del compuesto; composicion farmaceutica que comprende al compuesto y uso del compuesto; util para el tratamiento de enfe
BR0211905A (pt) Dialdeìdos de rapamicina
ES2065701T3 (es) Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas.
AR005009A1 (es) Monohidrato del cdch, procedimiento para su produccion , composiciones antibacteriales que lo contienen, uso del monohidrato del cdch para la manufactura de medicamentos.
PT1293196E (pt) Composicao farmaceutica compreendendo doxazosina
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
CU23043A1 (es) Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
BR0313220A (pt) Pelìcula de revestimento para comprimidos e cápsulas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
SE9804212D0 (sv) Compounds